Sol-Gel Technologies Ltd.
SLGL evidence brief
What we can confirm
- BioSniper Score:
- 9.6 / 10
- Market Cap:
- $215.9M
What it means
What to watch
Prepared research question
What matters most for SLGL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLGL
Sol-Gel Technologies Ltd. (SLGL) is a dermatology company developing topical treatments for rare and severe skin conditions, with its lead candidate SGT-610 (patidegib gel, 2%) in a pivotal Phase 3 trial for Gorlin syndrome.
Key risk: Modest cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$215.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Sol-Gel Technologies Ltd. (SLGL) is a dermatology company developing topical treatments for rare and severe skin conditions, with its lead candidate SGT-610 (patidegib gel, 2%) in a pivotal Phase 3 trial for Gorlin syndrome.
- Sol-Gel is a dermatology company pioneering treatments for patients with rare and severe skin conditions [news].
- The company's lead candidate, SGT-610 (patidegib gel, 2%), is in a pivotal Phase 3 clinical trial for Gorlin syndrome [news].
- The last patient completed the last scheduled study visit in the Phase 3 trial of SGT-610 as of September 2026 [news].
- Top-line results from the Phase 3 trial are expected in late November 2026 [news].
- Cash & equivalents were $11.0M and shareholders' equity was $22.8M as of 2025-12-31 [sec].
What works
- The company has completed the last patient visit in its pivotal Phase 3 trial, indicating progress toward a potential data readout [news].
- Sol-Gel has a clear near-term catalyst with top-line results expected in late November 2026 [news].
- The company maintains a positive shareholders' equity of $22.8M as of 2025-12-31, suggesting a solvent balance sheet [sec].
What to weigh
- The company's cash position of $11.0M as of 2025-12-31 is relatively modest for a biotech awaiting pivotal trial results, raising potential runway concerns [sec].
- The Phase 3 trial is for a niche indication (Gorlin syndrome), which may limit the commercial market size if approved [news].
- The company has no approved products or disclosed revenue streams, relying entirely on the success of its pipeline [sec].
From the filings
Quoted directly from source documents.
Last patient completed the last scheduled study visit in the pivotal Phase 3 trial of SGT-610 for Gorlin syndrome.
“Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome”
News · September 17, 2026
Top-line results from the Phase 3 trial are expected in late November 2026.
“Top-line results remain on track for late November 2026”
News · September 17, 2026
Sol-Gel is a dermatology company pioneering treatments for patients with rare and severe skin conditions.
“Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions”
News · September 17, 2026
Catalyst timeline
- 2019-12-20 · Phase 2 Start — Initiation of a Phase 2 study of patidegib topical gel 2% for reduction of BCC disease burden in non-Gorlin high-frequency BCC patients.
- 2024-03-17 · Phase 3 Start — Initiation of a pivotal Phase 3 study of patidegib gel 2% for reduction of BCC disease burden in Gorlin syndrome patients.
Risks & what to watch (3)›
Key risks
- Modest cash runway — Cash of $11.0M as of 2025-12-31 may be limited to fund operations through the expected late 2026 data readout [sec].
- Single-asset dependency — The company's pipeline is concentrated on SGT-610, with no approved products or disclosed revenue streams [news].
- Niche market size — Gorlin syndrome is a rare condition, potentially limiting the commercial opportunity even if the trial succeeds [news].
What to watch
- Top-line results from the Phase 3 trial of SGT-610, expected in late November 2026 [news].
- Cash runway and any financing or partnership announcements given the $11.0M cash position as of 2025-12-31 [sec].
- Regulatory interactions or FDA feedback following the Phase 3 data readout [news].
Sources: Catalysts · Competitor trials · News · Generated October 13, 2026 · How we verify sources →
Run Sol-Gel Technologies Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sol-Gel Technologies Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.31
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
10 buys · 0 sells (180d)
Financials
Short Interest
as of May 22, 2026- % of float
- 3.9%
- Days to cover
- 0.7
- Shares short
- 39,739
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLGL short interestFrequently asked questions
What is the AI investment thesis for Sol-Gel Technologies Ltd.?
Sol-Gel Technologies Ltd. (SLGL) is a dermatology company developing topical treatments for rare and severe skin conditions, with its lead candidate SGT-610 (patidegib gel, 2%) in a pivotal Phase 3 trial for Gorlin syndrome.
Who is the CEO of Sol-Gel Technologies Ltd.?
Mr. Moshe Arkin is the chief executive officer of Sol-Gel Technologies Ltd. (SLGL).
Where is Sol-Gel Technologies Ltd. headquartered?
Sol-Gel Technologies Ltd. (SLGL) is headquartered in Ness Ziona, Israel.
What therapeutic areas does Sol-Gel Technologies Ltd. focus on?
Sol-Gel Technologies Ltd. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.